Motivista delivers cognitive behavioral therapy techniques, including cognitive restructuring, behavioral activation, social skills training, and positive affect training, via lessons and daily check-ins.

Overview Debates Related claims Topics Sources

552c7ae14Claim

Childhood trauma leads people to develop psychosis

552c7ae14Claim

Mental health nursing expert Jill Archibald provided evidence to the Lampard Inquiry that Oxevision cameras can increase patient paranoia and cause some patients to scream at the device.

552c7ae14Claim

Valdo Calocane was diagnosed with paranoid schizophrenia in 2020, had been sectioned four times under the Mental Health Act, and pleaded guilty to manslaughter on the grounds of diminished responsibility in January 2024

552c7ae14Claim

A study of U.S. health data published in Lancet Psychiatry reported that GLP-1 users with schizophrenia and type 2 diabetes were less likely to be admitted to a psychiatric hospital than patients taking other types of diabetes medication

552c7ae14Claim

A study of U.S. health records published in Lancet Psychiatry found that patients with both schizophrenia and type 2 diabetes who were prescribed GLP-1 receptor agonists had a 24% lower risk of psychiatric hospital admission than those not taking GLP-1s

552c7ae14Claim

Patients with schizophrenia and type 2 diabetes prescribed GLP-1 receptor agonists were 29% less likely to visit an emergency department for a mental health crisis compared to those not taking GLP-1s, according to a Lancet Psychiatry study

552c7ae14Claim

The American College of Obstetricians and Gynecologists guidelines give conditional recommendations to cognitive behavioral therapy, mindfulness-based interventions, exercise, clinical hypnosis, and acupuncture for menopausal symptom relief, noting weaker evidence than for hormone therapy

552c7ae14Claim

The authors of the Lancet Psychiatry study published in October 2026 emphasized that randomized controlled trials are required to confirm whether GLP-1 receptor agonists directly reduce psychiatric acute care needs in patients with schizophrenia

552c7ae14Claim

Study authors advised that GLP-1 receptor agonists should not be considered a primary psychiatric treatment or prescribed solely to reduce psychiatric hospital admissions based on current evidence

552c7ae14Claim

Research published in Lancet Psychiatry found schizophrenia patients taking GLP-1 diabetes drugs had a 29% lower likelihood of emergency room visits for mental health crises compared to non-users.

552c7ae14Claim

A study in Lancet Psychiatry using U.S. health records showed people with schizophrenia taking GLP-1 drugs for diabetes were 24% less likely to be admitted to psychiatric hospitals.

552c7ae14Claim

Canada should exclude mental illness as a sole condition for medically assisted dying

552c7ae14Claim

Outro plans to use its $7 million in capital to expand its network of deprescribing clinicians and develop artificial intelligence clinical decision support tools.

552c7ae14Claim

Approximately one in six Americans take an antidepressant medication, and average duration of use has surpassed five years.

552c7ae14Claim

Outro's deprescribing platform incorporates personalized hyperbolic tapering plans, compounded medication doses, patient monitoring, and specially-trained clinicians.

552c7ae14Claim

Outro plans to expand its tapering model into additional medication classes beyond antidepressants, including benzodiazepines, gabapentinoids, and GLP-1s.

552c7ae14Claim

Research led by Dr. Mark Horowitz found that four in five long-term antidepressant users were unable to stop taking their medications due to withdrawal symptoms.

552c7ae14Claim

Hyperbolic tapering is the most effective protocol for discontinuing psychiatric medications

552c7ae14Claim

Commercial digital platforms are suitable for managing complex psychiatric drug withdrawal

552c7ae14Claim

Childhood trauma leads people to develop psychosis

Mental health nursing expert Jill Archibald provided evidence to the Lampard Inquiry that Oxevision cameras can increase patient paranoia and cause some patients to scream at the device.

Valdo Calocane was diagnosed with paranoid schizophrenia in 2020, had been sectioned four times under the Mental Health Act, and pleaded guilty to manslaughter on the grounds of diminished responsibility in January 2024

A study of U.S. health data published in Lancet Psychiatry reported that GLP-1 users with schizophrenia and type 2 diabetes were less likely to be admitted to a psychiatric hospital than patients taking other types of diabetes medication

A study of U.S. health records published in Lancet Psychiatry found that patients with both schizophrenia and type 2 diabetes who were prescribed GLP-1 receptor agonists had a 24% lower risk of psychiatric hospital admission than those not taking GLP-1s

Patients with schizophrenia and type 2 diabetes prescribed GLP-1 receptor agonists were 29% less likely to visit an emergency department for a mental health crisis compared to those not taking GLP-1s, according to a Lancet Psychiatry study

The American College of Obstetricians and Gynecologists guidelines give conditional recommendations to cognitive behavioral therapy, mindfulness-based interventions, exercise, clinical hypnosis, and acupuncture for menopausal symptom relief, noting weaker evidence than for hormone therapy

The authors of the Lancet Psychiatry study published in October 2026 emphasized that randomized controlled trials are required to confirm whether GLP-1 receptor agonists directly reduce psychiatric acute care needs in patients with schizophrenia

Study authors advised that GLP-1 receptor agonists should not be considered a primary psychiatric treatment or prescribed solely to reduce psychiatric hospital admissions based on current evidence

Research published in Lancet Psychiatry found schizophrenia patients taking GLP-1 diabetes drugs had a 29% lower likelihood of emergency room visits for mental health crises compared to non-users.

A study in Lancet Psychiatry using U.S. health records showed people with schizophrenia taking GLP-1 drugs for diabetes were 24% less likely to be admitted to psychiatric hospitals.

Canada should exclude mental illness as a sole condition for medically assisted dying

Outro plans to use its $7 million in capital to expand its network of deprescribing clinicians and develop artificial intelligence clinical decision support tools.

Approximately one in six Americans take an antidepressant medication, and average duration of use has surpassed five years.

Outro's deprescribing platform incorporates personalized hyperbolic tapering plans, compounded medication doses, patient monitoring, and specially-trained clinicians.

Outro plans to expand its tapering model into additional medication classes beyond antidepressants, including benzodiazepines, gabapentinoids, and GLP-1s.

Research led by Dr. Mark Horowitz found that four in five long-term antidepressant users were unable to stop taking their medications due to withdrawal symptoms.

Hyperbolic tapering is the most effective protocol for discontinuing psychiatric medications

Commercial digital platforms are suitable for managing complex psychiatric drug withdrawal

U.S. healthcare providers should prioritize deprescribing over long-term psychiatric medication maintenance